BMRN·BioMarin Pharmaceutical Inc.
BMRN|Analyst Targets
BMRN|Insider Trading
BMRN|Fundamentals
BMRN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.95 | - | - |
| Q1'26 | $0.81 | $0.76 | -6.2% |
| Q1'25 | $0.95 | $1.13 | +18.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.0B | - | - |
| Q1'26 | $771M | $766M | -0.6% |
| Q1'25 | - | $745M | - |
BMRN|Monthly Returns
Market Data
BMRN Stock Snapshot
- Market cap
- 10.57B
- P/E ratio
- 144.9
- Day range
- $54.37 – $55.56
- News sentiment
- 58/100 · Neutral
- Analyst target
- $91.62 (+65.8%)
- Consensus
- Buy · 37 analysts
The signal on BMRN is bullish: price action is confirming the underlying trend, not fighting it. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.
Behaviour On Record
What BMRN's own history says about today's numbers
- Realized volatility (21d)
- 23.8% 17th pct
- Below its peak
- -63.0%
- vs 200-day average
- -5.9%
- Up days (1y)
- 46%
BioMarin Pharmaceutical Inc. is currently running 23.8% annualised volatility over the last 21 sessions. Measured against BMRN's own 13 years of daily returns rather than a market-wide average, that is the 17th percentile — unusually subdued by its own history, against a typical reading of 32.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
BMRN is trading -63.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -34.1%, and the deepest was -44.9% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -5.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 35th percentile — close to the gap it normally carries. Over the past year BMRN closed higher on 46% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 14 years of records, BMRN finished the month higher 4 of 14 times, with a median return of -4.0% and an average of -1.5%. Its strongest month historically has been November at +5.4% on average, its weakest September at -6.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: BMRN has opened more than 2% away from the prior close in 199 of 3,267 sessions (6.1% of the time), with the largest gaps running +9.3% and -10.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against BMRN's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of BMRN's sector?
BioMarin Pharmaceutical Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, BMRN ranks 9th of 15 tracked industries, improving.
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 82
- Industry rank
- #9 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on BMRN?
Barclays most recently reiterated its rating on BioMarin Pharmaceutical Inc. to Overweight on Oct 14, 2026 with a price target of $114 (from $111). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Barclays — Overweight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Earnings Release, Scored
What did BioMarin Pharmaceutical Inc.'s latest earnings release say?
Most important lines
- 1
“Strong global demand led us to increase full-year VOXZOGO revenue guidance to at least $1 billion in 2026.
Guidance raised - 2
Strong U.S. and global demand led to increased full-year 2026 VOXZOGO revenue guidance to a low end of $1 billion.
Guidance raised - 3
The company is targeting gross leverage below 2.5 times by mid-year 2027, an acceleration by approximately one year of prior timeline guidance provided at deal announcement, supported by profitability growth of the combined company.
Guidance raised
ETF holders
ETFs holding BMRN
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | ▲ Buy | 20,445,212 | 10.52% | $1.17B | 2026-08-07 |
| Vanguard Group Inc | ▼ Sell | 18,127,847 | 9.32% | $1.08B | 2026-01-29 |
| Norges Bank | ▲ Buy | 8,207,954 | 4.22% | $469.66M | 2026-08-12 |
| Viking Global Investors LP | ▲ Buy | 7,616,563 | 3.92% | $435.82M | 2026-08-14 |
| AQR Capital Management LLC | ▼ Sell | 5,699,541 | 2.93% | $322.54M | 2026-08-14 |
| FMR LLC (Fidelity) | ▲ Buy | 4,822,893 | 2.48% | $275.97M | 2026-08-13 |
| Geode Capital Management, LLC | ▲ Buy | 3,911,794 | 2.01% | $223.89M | 2026-08-12 |
| Capital Research Global Investors | ▲ Buy | 3,504,387 | 1.80% | $200.52M | 2026-08-12 |
| Millennium Management LLC | ▼ Sell | 2,071,816 | 1.07% | $118.55M | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 1,558,104 | 0.80% | $89.15M | 2026-08-13 |
| Morgan Stanley | ▲ Buy | 1,504,989 | 0.77% | $86.12M | 2026-08-13 |
| Goldman Sachs Group Inc | ▲ Buy | 1,201,977 | 0.62% | $68.78M | 2026-08-14 |
| Citadel Advisors LLC | ▼ Sell | 1,122,408 | 0.58% | $64.22M | 2026-09-02 |
| Balyasny Asset Management L.P. | ▼ Sell | 1,054,613 | 0.54% | $60.34M | 2026-08-14 |
| Janus Henderson Group plc | ▲ Buy | 857,010 | 0.44% | $48.41M | 2026-05-18 |
| Loomis Sayles & Co L P | ▼ Sell | 713,657 | 0.37% | $40.84M | 2026-08-14 |
| JPMorgan Chase & Co | ▲ Buy | 694,550 | 0.36% | $40.57M | 2026-08-12 |
| Palo Alto Investors LP | ▼ Sell | 682,777 | 0.35% | $39.07M | 2026-08-19 |
| Bank of America Corp | ▼ Sell | 663,163 | 0.34% | $37.95M | 2026-08-14 |
| Invesco Ltd. | ▲ Buy | 494,604 | 0.25% | $28.30M | 2026-08-14 |
| Renaissance Technologies LLC | ▼ Sell | 451,871 | 0.23% | $25.86M | 2026-08-13 |
| Prudential Financial Inc | ▲ Buy | 392,811 | 0.20% | $22.48M | 2026-08-12 |
| Man Group plc | ▲ Buy | 367,981 | 0.19% | $21.06M | 2026-08-14 |
| AllianceBernstein L.P. | ▲ Buy | 283,400 | 0.15% | $16.01M | 2026-08-14 |
| Bridgewater Associates, LP | ▲ Buy | 274,911 | 0.14% | $15.73M | 2026-08-14 |